Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lululemon Athletica Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.85 (market cap $868.62M), while Lululemon Athletica Inc trades at $121.32 (market cap $14.26B). The key difference: Lululemon Athletica Inc is far larger — about 16.4× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | LULU | |
|---|---|---|
Market Cap | $868.62M | $14.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $215.88 |
52-Week Low | $16.87 | $105.43 |
Enterprise Value | $1.27B | $14.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Lululemon (LULU) trades at $121.4, down 5.01% amid broader market weakness in the premium apparel sector. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.69 beating expectations of $1.67. Valuation metrics appear attractive with P/E of 10.17 and P/S of 1.32, while profitability remains robust with 55.7% gross margins and 32.03% ROE. Technical indicators show a bullish moving average trend despite overbought RSI readings.
LULU presents a compelling investment case with undervalued metrics and strong international growth potential, particularly in China. However, risks include U.S. market softness and competitive pressures in the premium activewear space. The consensus price target of $129.29 suggests 6.5% upside potential from current levels, supported by 40.85% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
